
    
      To assess the incidence and nature of potential long-term safety outcomes (follow-up period
      up to 7 years) in patients with unresectable or metastatic, well-differentiated, somatostatin
      receptor positive gastroenteropancreatic neuroendocrine tumours. Retrospective and
      prospective data will be used.
    
  